Course

The Impact of Obesity in Patients with Rheumatoid Arthritis

We will look at the association between obesity and rheumatoid arthritis and how the presence of excess weight impacts patient experience and response to disease modifying anti-rheumatic drug therapy. We will also briefly address current thinking surrounding the “obesity paradox.” Lastly, we will explore approaches to weight loss in patients who are overweight or obese and the general benefits of weight loss in this population.

0 Lessons

Start Course

The Impact of Obesity in Patients with Rheumatoid Arthritis

PROVIDED BY

Support for this activity has been made possible through educational grants from Lilly, AbbVie, and Pfizer

TARGET AUDIENCE

This activity has been designed to meet the educational needs of nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.

ACTIVITY DESCRIPTION

In this issue of Rheumatology Nurse Practice, we’ll look at the association between obesity and rheumatoid arthritis and how the presence of excess weight impacts patient experience and response to disease modifying anti-rheumatic drug therapy. We will also briefly address current thinking surrounding the “obesity paradox.” Lastly, we will explore approaches to weight loss in patients who are overweight or obese and the general benefits of weight loss in this population.

LEARNING OBJECTIVES

After participating in the activity, learners should be better able to:

  • Discuss the impact of excess weight on the development and progression of RA
  • Assess the impact of anti-TNFs, non-TNF biologics, and small molecule therapeutics on weight in patients with RA
  • Analyze the evidence surrounding the “obesity paradox”
  • Identify current obese patients with RA who may benefit from referral to a bariatric center of excellence

DISCLOSURE STATEMENT

According to the disclosure policy of the Rheumatology Nurses Society, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

RELATIONSHIPS ARE ABBREVIATED AS FOLLOWS:

E: Educational planning committee
G: Grant/research support recipient
A: Advisor/review panel member
C: Consultant
S: Stock shareholder
SB: Speaker bureau
PE: Promotional event talks
H: Honoraria
O: Other

DISCLOSURES AS FOLLOWS:

Iris Zink, MSN, NP, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie, Crescendo Biosciences, Horizon/SB; Pfizer/C.

Carrie Beach, RN-BC, BSN, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Pfizer, Horizon, Novartis/A.

Jacqueline Fritz, RN, MSN, CNS, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Lilly, AbbVie, Celgene, Horizon, Momenta Pharmaceuticals/A; Celgene, AbbVie, Genentech, Horizon/SB.

Cathy Patty-Resk, MSN, RN-BC, CPNP-PC, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

PLANNING COMMITTEE

Kim Cheramie, MSN, RN-BC, Lead Nurse Planner, Rheumatology Nurses Society, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Scott Kober, MBA, President, MedCaseWriter, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Laura Trimingham, MD, Medical Writer, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Kevin D. Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

INDEPENDENT CLINICAL PEER REVIEWER
This newsletter was reviewed by Tiffany Clark, CNP. Ms. Clark has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

OFF-LABEL PRODUCT DISCLOSURE

There will be no discussion of investigational and/or off-label use of pharmaceutical products or devices within this activity.

ACCREDITATION AND CREDIT DESIGNATION

Nurses

Rheumatology Nurses Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500).

Rheumatology Nurses Society designates this educational activity for:
3.2 contact hours
2.8 pharmacotherapeutic contact hours

METHOD OF PARTICIPATION

There are no fees to participate in the activity. Participants must review the activity information, including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE credit for your participation, please go to rnsnurse.com/rnpce and complete the post-test (achieving a passing grade of 70% or greater) and program evaluation. Your certificate will be emailed to you upon completion.

COPYRIGHT

© 2018. This CNE-certified activity is held as copyrighted © by Rheumatology Nurses Society. Through this notice, the Rheumatology Nurses Society grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).